Insider · CIK 0001454983
Richard S Levy
director
Files at MDGL (MADRIGAL PHARMACEUTICALS, INC.), TARA (Protara Therapeutics, Inc.), KNSA (Kiniksa Pharmaceuticals International, plc). First filing Nov 5, 2024, latest May 19, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
2 / 2
$128k bought, $3.3M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MDGL: MADRIGAL PHARMACEUTICALS, INC.
MDGLOct 9, 2026 · close 471.75
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | TARAbuy Protara Therapeutics, Inc. | $64k 20,000 shares | +65% | - | |
| 33Weak | TARAbuy Protara Therapeutics, Inc. | $64k 20,000 shares | +65% | - | |
| 23Weak | MADRIGAL PHARMACEUTICALS, INC. | $1.8M 5,000 shares | -31% | - | |
| 15Weak | MADRIGAL PHARMACEUTICALS, INC. | $1.5M 5,000 shares | -31% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 20, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | AGrant or award Common Stock | +715 | $0.00 | $0 | 21,197 | Jun 24, 2025 |
| Jun 20, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +1,290 | $0.00 | $0 | 1,290 | Jun 24, 2025 |
| Jun 12, 2025 | TARA Protara Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 13, 2025 |
| Jun 5, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share | +3,173 | - | - | 17,373 | Jun 5, 2025 |
| Jun 3, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | AGrant or award Share Optionderivative | +16,798 | $0.00 | $0 | 16,798 | Jun 5, 2025 |
| Jun 3, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | AGrant or award Restricted Share Unitsderivative | +2,799 | $0.00 | $0 | 2,799 | Jun 5, 2025 |
| Jun 5, 2025 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitsderivative | -3,173 | $0.00 | $0 | 0 | Jun 5, 2025 |
| May 14, 2025 | TARA Protara Therapeutics, Inc. | POpen-market purchase Common Stock | +20,000 | $3.19 | $64k | 51,000 | May 19, 2025 |
| May 14, 2025 | TARA Protara Therapeutics, Inc. | POpen-market purchase Common Stock | +20,000 | $3.19 | $64k | 51,000 | May 16, 2025 |
| Apr 10, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | MOption exercise Common Stock | +9,470 | $65.06 | $616k | 20,482 | Apr 11, 2025 |
| Apr 10, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | MOption exercise Stock Option (Right to Buy)derivative | -9,470 | $0.00 | $0 | 0 | Apr 11, 2025 |
| Nov 7, 2024 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Class A Ordinary Share | +1,303 | - | - | 14,200 | Nov 12, 2024 |
| Nov 7, 2024 | KNSA Kiniksa Pharmaceuticals International, plc | AGrant or award Restricted Share Unitsderivative | +1,303 | $0.00 | $0 | 1,303 | Nov 12, 2024 |
| Nov 7, 2024 | KNSA Kiniksa Pharmaceuticals International, plc | MOption exercise Restricted Share Unitsderivative | -1,303 | $0.00 | $0 | 0 | Nov 12, 2024 |
| Nov 7, 2024 | MDGL MADRIGAL PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +5,000 | $7.36 | $37k | 16,012 | Nov 8, 2024 |
| Nov 7, 2024 | MDGL MADRIGAL PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -5,000 | $350.00 | $1.8M | 11,012 | Nov 8, 2024 |
| Nov 7, 2024 | MDGL MADRIGAL PHARMACEUTICALS, INC. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 5,000 | Nov 8, 2024 |
| Nov 1, 2024 | MDGL MADRIGAL PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +5,000 | $7.36 | $37k | 16,012 | Nov 5, 2024 |
| Nov 1, 2024 | MDGL MADRIGAL PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -2,800 | $300.10 | $840k | 13,212 | Nov 5, 2024 |
| Nov 1, 2024 | MDGL MADRIGAL PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -1,100 | $301.22 | $331k | 12,112 | Nov 5, 2024 |
| Nov 1, 2024 | MDGL MADRIGAL PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -800 | $302.25 | $242k | 11,312 | Nov 5, 2024 |
| Nov 1, 2024 | MDGL MADRIGAL PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -300 | $304.29 | $91k | 11,012 | Nov 5, 2024 |
| Nov 1, 2024 | MDGL MADRIGAL PHARMACEUTICALS, INC. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 10,000 | Nov 5, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.